腎癌組織組蛋白去乙酰化酶1、p73及血清IL—17表達的臨床意義

那日蘇

[摘要] 目的 探究腎癌組織組蛋白去乙酰化酶1、p73及血清IL-17表達的臨床意義。 方法 方便選取于2015年1月—2016年12月該院收治的腎癌患者80例作為腎癌組，同期入院接受血液檢查的健康人20名作為健康對照組。取腎癌患者瘤體邊緣無壞死的腫瘤組織作為病理標本，取瘤旁正常組織作為正常標本，運用免疫組織化學法（S-P法）將標本進行染色，統(tǒng)計HDAC-1及p73陽性細胞，計算陽性率；抽取腎癌患者及健康對照組靜脈血，ELISA法對兩組血液進行IL-17含量檢測。 結果 腎癌患者的腎癌組織中HDAC-1及p73的陽性率高達81.25%和77.50%，顯著高于正常腎旁組織（P<0.001）；且隨著臨床分型的提高，HDAC-1及p73的陽性率隨之提高（P<0.05）；Ⅲ期和Ⅳ期腎癌患者的HDAC-1及p73的陽性率高達100.00%；Ⅰ期和Ⅱ期腎癌患者HDAC-1及p73的陽性率分別為69.56%，86.11%和56.63%，77.78%；腎癌患者血清IL-17含量隨著臨床分型的升高而升高，Ⅱ期、Ⅲ期、Ⅳ期腎癌患者血清IL-17含量分別高達（173.27±39.74）、（186.88±42.55）pg/mL和（189.45±15.84）pg/mL，與Ⅰ期患者相比含量顯著增加（P<0.05）。結論 腎癌組織HDAC-1和p73的表達顯著高于腎旁正常組織，且隨著臨床分型的增高而增加；腎癌患者外周血中IL-17的表達顯著高于健康對照組，且隨著臨床分型的增高而增加。提示HDAC-1、p73及IL-17可能是促進腎癌發(fā)生發(fā)展的重要因子。

[關鍵詞] HDAC-1；p73；IL-7；腎癌

[中圖分類號] R737 [文獻標識碼] A [文章編號] 1674-0742（2017）08（c）-0005-04

Clinical Significance of Renal Cell Carcinoma Histone Deacetylases 1， p73 and Serum IL-17 Expression

NA Ri-su

Department of Urinary Surgery， First Affiliated Hospital of Baotou Medical College， Baotou， Inner Mongolia， 014010 China

[Abstract] Objective To study the clinical significance of renal cell carcinoma histone deacetylases 1、p73 and serum IL-17 expression. Methods 80 cases of patients with renal carcinoma admitted and treated in our hospital from January 2015 to December 2016 were selected as the renal carcinoma group， 20 cases of healthy patients with blood examination at the same period were selected as the healthy control group， and the tumor tissues whose tumor margin had no necrosis were selected as the pathological specimens， and normal tissues were selected as the normal specimens， and the specimens were dyed by the ？？immunohistochemical method？， and the HDAC-1 and p73 positive cells were counted and the positive rate was calculated and the venous blood was extracted from the renal cancer patients and healthy control patients， and the IL-17 content of the two groups was tested by the ELISA method. Results The positive rates of HDAC-1 and p73 in the renal cancer tissues in renal cancer patients were respectively 81.25% and 77.50%， which were obviously higher than those of normal tissues（P<0.01）， with the increase of clinical typing， the positive rates of HDAC-1 and p73 increases（P<0.05）， and the positive rate of HDAC-1 and p73 of renal cancer patients during the Ⅲ period and Ⅳ period were as high as 100.00%， and the positive rates of HDAC-1 and p73 of renal cancer patients during the Ⅰ period and Ⅱ period were respectively 69.56%，86.11% and 56.63%，77.78%， with the increase of clinical typing， the serum IL-17 content also increase， the serum IL-17 contents of renal cancer patients during the Ⅱ period， Ⅲ period and Ⅳ period were respectively （173.27±39.74）、（186.88±42.55）pg/mL and（189.45±15.84）pg/mL， and the content obviously increased compared with that of patients during the Ⅰ period（P<0.05）. Conclusion The expression of renal cancer tissues HDAC-1 and p73 was obviously higher than that of normal tissues， with the increase of clinical typing， the expression also increases， which reminds that the HDAC-1， p73 and IL-17 may be the important factors of promoting the occurrence and development of renal cancer.endprint